Anti-inflammatory injections may significantly reduce the risk of secondary cardiovascular disease without the need for statins, a study has found.
Patients who had injections of an anti-inflammatory monoclonal antibody were less likely to suffer a new cardiovascular event.
The study, led by a team from Brigham and Women’s Hospital in Boston and funded by Novartis, allocated just over 10,000 patients with a previous history of heart attack to receive either the anti-inflammatory injection (canakinumab) or a placebo.
Patients who received the second highest dose of canakinumab had a 15% reduction in risk of subsequent cardiovascular events after 48 months of follow up compared to those who took a placebo.
Lipid levels in patients receiving canakinumab did not reduce significantly from baseline, suggesting that the benefits of the drug in reducing cardiovascular disease risk occur independently of lipid-lowering action.
Cancer mortality in patients who received canakinumab was also significantly lower than in patients who had the placebo.
There were, however, significantly more deaths from infection or sepsis in the canakinumab group compared to the placebo, and no significant difference between the groups in deaths from any cause.
Canakinumab works by targeting an interleukin involved in the inflammatory pathway, which has been associated with increased risk of cardiovascular events in previous research.
Dr Chris Arden, GPSI in cardiology in Southampton, said: ’This research poses more questions than answers at this stage but it opens up the idea of using inflammatory markers as a potential way of risk-stratifying patients.
‘We all recognise that inflammation is important in atherosclerotic disease and this suggests that treating it is of potential benefit, but we’ll need a lot more evidence before this can be embedded in to clinical practice.
‘The potential is exciting but I think we’re at the start of a journey – statins will be around for a while to come.’